Overview

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, parallel-controlled, multicenter clinical trial in primary hyperuricemia patients with or without gout.
Phase:
Phase 2
Details
Lead Sponsor:
InventisBio Co., Ltd
Treatments:
Benzbromarone